Anthony Scilipoti, Veritas Investment Research president and chief executive officer, reacts to the decision by a panel of FDA experts who voted unanimously that Valeant's plaque psoriasis drug, brodalumab, deserved approval. He speaks with Bloomberg's Vonnie Quinn and David Gura on "Bloomberg Markets." (Source: Bloomberg)